NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc RPRX announced today that its Board of Directors has declared a dividend of $0.20 per Class A share for the first quarter of 2023, representing a 5.3% increase in the Company’s quarterly dividend from the prior quarter’s dividend is equivalent to. The dividend will be paid on March 15, 2023 to shareholders of record at the close of business on February 16, 2023.

“We are pleased to announce another increase in our dividend,” said Pablo Legorreta, Founder and Chief Executive Officer of Royalty Pharma. “We are committed to returning capital to our shareholders through our attractive dividend while maintaining the financial flexibility to fund innovation. We continue to see significant opportunities for value-added growth as demand for capital in the biopharma ecosystem remains very strong.”

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalty payments and a leading enabler of innovation across the biopharmaceutical industry, working with innovators from academic institutions, research hospitals and not-for-profit organizations, to small and mid-sized biotechnology companies, to leading global pharmaceutical companies. Royalty Pharma has assembled a royalty portfolio that entitles it to payments based directly on the sales of many industry-leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it works with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalty payments on more than 35 commercial products including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ Xtandi and Pfizer, GSK’s Trelegy, Promacta by Novartis, Nurtec by Pfizer…